Skip to main content

Advertisement

Table 3 Comparison of age, duration of disease, final dose, frequency of administration of canakinumab and number of adjustments (dose and/or frequency) performed during 12 months in patients with MWS and CINCA

From: The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age

  Muckle-Wells (6 patients)1 CINCA (7 patients) P-value2
Age, years, median (range) 13.6 (10.7, 23.7) 15 (8.7, 38.0) 0.56*
Disease duration, median, years (range) 13,6 (3.0, 23.2) 15 (8.7, 38.0) 0.61*
Dose, mg/kg, median (range) 2.15 (2.0, 3.7) 3.7 (2.0, 5.9) 0.16*
Frequency, weeks, median (range) 8 (6, 10) 6 (4, 8) 0.03
Adjustments/year, number 2 9 0.05
  1. 1Includes two patients with a Muckle-Wells syndrome (MWS)/chronic infantile neurological cutaneous and articular syndrome (CINCA) phenotype; 2Mann-Whitney U-test, *not significant.